Vision-related quality of life and visual function following intravitreal bevacizumab injection for persistent diabetic macular edema after vitrectomy

Japanese Journal of Ophthalmology

Volumn 58, Issue 4, 2014, Pages 369-374

  Okamoto, Yoshifumi ^a   Okamoto, Fumiki ^a   Hiraoka, Takahiro ^a   Oshika, Tetsuro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Bevacizumab; Diabetic macular edema; Vitrectomized

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ANTAGONISTS AND INHIBITORS; CONTRAST SENSITIVITY; DIABETIC RETINOPATHY; FEMALE; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PHYSIOLOGY; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; SICKNESS IMPACT PROFILE; VISION; VISUAL ACUITY; VITRECTOMY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CONTRAST SENSITIVITY; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISION, OCULAR; VISUAL ACUITY; VITRECTOMY;

EID: 84905823162     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-014-0323-7     Document Type: Article

References (34)

1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol. 1985;103:1796-806.
2. Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol. 2005;139:290-4. (Pubitemid 40288274)
3. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-7. (Pubitemid 34465226)
4. Rosenblatt BJ, Shah GK, Sharma S, Bakal J. Pars plana vitrectomy with internal limiting membranectomy for refractory diabetic macular edema without a taut posterior hyaloid. Graefes Arch Clin Exp Ophthalmol. 2005;243:20-5.
5. Recchia FM, Ruby AJ, Carvalho Recchia CA. Pars plana vitrectomy with removal of the internal limiting membrane in the treatment of persistent diabetic macular edema. Am J Ophthalmol. 2005;139:447-54. (Pubitemid 40379070)
6. Abe S, Yamamoto T, Kashiwagi Y, Kirii E, Goto S, Yamashita H. Three-dimensional imaging of the inner limiting membrane folding on the vitreomacular interface in diabetic macular edema. Jpn J Ophthalmol. 2013;57:553-62.
7. Tamura K, Yokoyama T, Ebihara N, Murakami A. Histopathologic analysis of the internal limiting membrane surgically peeled from eyes with diffuse diabetic macular edema. Jpn J Ophthalmol. 2012;56:280-7.
8. Okamoto F, Okamoto Y, Fukuda S, Hiraoka T, Oshika T. Visionrelated quality of life and visual function after vitrectomy for various vitreoretinal disorders. Investig Ophthalmol Vis Sci. 2010;51:744-51.
9. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M et al Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007;114:743-50. (Pubitemid 46483714)
10. Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina. 2007;27:1187-95. (Pubitemid 350211523)
11. Arimura E, Matsumoto C, Okuyama S, Takada S, Hashimoto S, Shimomura Y. Quantification of metamorphopsia in a macular hole patient using M-CHARTS. Acta Ophthalmol Scand. 2007;85:55-9. (Pubitemid 46140157)
12. Matsumoto C, Arimura E, Okuyama S, Takada S, Hashimoto S, Shimomura Y. Quantification of metamorphopsia in patients with epiretinal membranes. Investig Ophthalmol Vis Sci. 2003;44:4012-6. (Pubitemid 37047977)
13. Pelli DG, Robson G, Wilkins AJ. The designed of a new letter chart for measuring contrast sensitivity. Clin Vis Sci. 1988;2:187-99.
14. Maeda N, Sato S, Watanabe H, Inoue Y, Fujikado T, Shimamura Y, et al. Prediction of letter contrast sensitivity using videokeratographic indices. Am J Ophthalmol. 2000;129:759-63. (Pubitemid 30604155)
15. Elliott DB, Bullimore MA, Bailey IL. Improving the reliability of the Pelli-Robson contrast sensitivity test. Clin Vis Sci. 1991;6:471-5.
16. Mangione CM, Lee PP, Gutierrez PR, Spitzer K, Berry S, Hays RD. National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050-8. (Pubitemid 32652197)
17. Suzkamo Y, Oshika T, Yuzawa M, Tokuda Y, Tomidokoro A, Oki K, et al. Psychometric properties of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25), Japanese version. Health Qual Life Outcomes. 2005;3:65.
18. Yanyali A, Horozoglu F, Celik E, Nohutcu AF. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina. 2007;27:557-66. (Pubitemid 46905145)
19. Stefánsson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol. 2009;247:147-63.
20. Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Investig Ophthalmol Vis Sci. 2012;53:5877-80.
21. Chou TH, Wu PC, Kuo JZ, Lai CH, Kuo CN. Relationship of diabetic macular oedema with glycosylated haemoglobin. Eye (Lond). 2009;23:1360-3.
22. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol. 2008;126:1707-15.
23. Itoh-Tanimura M, Hirakata A, Itoh Y, Sano ME, Inoue M, Ishida H. Relationship between compliance with ophthalmic examinations preoperatively and visual outcome after vitrectomy for proliferative diabetic retinopathy. Jpn J Ophthalmol. 2012;56:481-7.
24. Mehta S, Blinder KJ, Shah GK, Kymes SM, Schlief SL, Grand MG. Intravitreal bevacizumab for the treatment of refractory diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2010;41:323-9.
25. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol. 2007;144:124-6. (Pubitemid 46963178)
26. Amsler M. Earliest symptoms of disease of the macula. Br J Ophthalmol. 1953;37:521-37.
27. Gass JDM, Norton EWD. Cystoid macular edema and papilledema following cataract extraction. Arch Ophthalmol. 1966;76:646-61.
28. Okamoto F, Sugiura Y, Okamoto Y, Hiraoka T, Oshika T. Associations between metamorphopsia and foveal microstructure in patients with epiretinal membrane. Investig Ophthalmol Vis Sci. 2012;53:6770-5.
29. Owsley C, Sloane ME. Contrast sensitivity, acuity, and the perception of "real-world" targets. Br J Ophthalmol. 1987;71:791-6. (Pubitemid 17148511)
30. Lennerstrand G, Ahlstrom CO. Contrast sensitivity in macular degeneration and the relation to subjective visual impairment. Acta Ophthalmol (Copenh). 1989;67:225-33. (Pubitemid 19184344)
31. Leat SJ, Woodhouse JM. Reading performance with low vision aids: relationship with contrast sensitivity. Ophthalmic Physiol Opt. 1993;13:9-16. (Pubitemid 23078529)
32. Rubin GS, Roche KB, Prasada-Rao P, Fried LP. Visual impairment and disability in older adults. Optom Vis Sci. 1994;71:750-60.
33. Okamoto F, Okamoto Y, Hiraoka T, Oshika T. Vision-related quality of life and visual function after retinal detachment surgery. Am J Ophthalmol. 2008;146:85-90.
34. Nagasawa T, Naito T, Matsushita S, Sato H, Katome T, Shiota H. Efficacy of intravitreal bevacizumab (Avastin) for short-term treatment of diabetic macular edema. J Med Invest. 2009;56:111-5.